Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, welcomes CPHI Milan attendees to explore the synergistic potential of its expanded excipients portfolio, a year after the acquisition of leading capsule manufacturer, Qualicaps.
At the event, Roquette will showcase its new strategic direction through cutting-edge insights, samples, and product demonstrations, all of which highlight how together, Roquette and Qualicaps unlock healthier futures.
Surveying the synergies
Twelve months on from the announcement at CPHI 2023, Roquette’s acquisition of Qualicaps has solidified its position as a leading, end-to-end solutions provider for oral dosage forms. Both companies hold strong positions in their respective markets and stand at the forefront of innovation, universally recognized as top-tier global players. Now, their blended expertise allows Roquette to offer everything from fillers, binders, encapsulants, disintegrants, lubricants, and more, as well as the high-quality capsules that house the final product. What’s more, the combination of the companies’ manufacturing assets, supply chain, in-depth customer knowledge, and commercial and technical capabilities provide drug producers with a solid, unified foundation for exceptional service quality, wherever they are based.
“It’s incredible to see the impact the acquisition has had in just 12 short months, particularly in terms of knowledge sharing and the exploration of complementary synergies between our companies,” comments Paul Smaltz, Vice President of Pharmaceutical Solutions at Roquette. “Looking to the future, we’ll continue our review of the Roquette and Qualicaps portfolios, searching for new combined solutions to help our customers unlock brighter, better, more innovative treatments for patients.”
Join the experts at booth 6A58 to learn more about the expanded potential of the Roquette and Qualicaps portfolio.
